Srinivas Ayyadevara
Concepts (286)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Caenorhabditis elegans | 28 | 2024 | 146 | 5.550 |
Why?
| Alzheimer Disease | 9 | 2024 | 367 | 2.720 |
Why?
| Longevity | 13 | 2019 | 87 | 2.480 |
Why?
| Caenorhabditis elegans Proteins | 12 | 2019 | 60 | 2.170 |
Why?
| Neurodegenerative Diseases | 4 | 2022 | 83 | 2.000 |
Why?
| Phosphatidylinositol 3-Kinases | 6 | 2016 | 153 | 1.420 |
Why?
| Phosphatidylinositol Phosphates | 3 | 2018 | 15 | 1.270 |
Why?
| Aging | 5 | 2016 | 784 | 1.260 |
Why?
| 14-3-3 Proteins | 2 | 2022 | 24 | 1.040 |
Why?
| Aspirin | 3 | 2017 | 127 | 1.030 |
Why?
| Creutzfeldt-Jakob Syndrome | 1 | 2022 | 7 | 0.900 |
Why?
| Animals | 36 | 2024 | 14385 | 0.860 |
Why?
| Oxidative Stress | 6 | 2012 | 958 | 0.850 |
Why?
| Peptide Chain Elongation, Translational | 1 | 2021 | 7 | 0.800 |
Why?
| DNA | 3 | 2021 | 581 | 0.790 |
Why?
| Glutathione Transferase | 3 | 2006 | 178 | 0.780 |
Why?
| Chromosome Mapping | 4 | 2006 | 175 | 0.730 |
Why?
| RNA | 1 | 2021 | 202 | 0.720 |
Why?
| RNA Interference | 7 | 2016 | 195 | 0.710 |
Why?
| Proteomics | 3 | 2018 | 343 | 0.700 |
Why?
| Somatomedins | 1 | 2018 | 29 | 0.670 |
Why?
| Hippocampus | 2 | 2021 | 242 | 0.660 |
Why?
| Membrane Proteins | 3 | 2018 | 389 | 0.630 |
Why?
| Mutation | 6 | 2016 | 1501 | 0.610 |
Why?
| Proteins | 2 | 2018 | 376 | 0.610 |
Why?
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2016 | 10 | 0.580 |
Why?
| Muscles | 1 | 2016 | 114 | 0.570 |
Why?
| Insulin | 1 | 2018 | 510 | 0.550 |
Why?
| Aldehydes | 2 | 2006 | 97 | 0.540 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2018 | 131 | 0.520 |
Why?
| Amyloid beta-Peptides | 4 | 2021 | 82 | 0.510 |
Why?
| Quantitative Trait Loci | 2 | 2006 | 51 | 0.510 |
Why?
| Lipids | 2 | 2016 | 178 | 0.490 |
Why?
| Proteasome Inhibitors | 1 | 2014 | 110 | 0.480 |
Why?
| Brain | 2 | 2018 | 1387 | 0.450 |
Why?
| Gene Knockdown Techniques | 3 | 2016 | 125 | 0.410 |
Why?
| Animals, Genetically Modified | 4 | 2018 | 52 | 0.380 |
Why?
| Hypertension | 1 | 2016 | 564 | 0.380 |
Why?
| Cardiovascular Diseases | 1 | 2016 | 476 | 0.370 |
Why?
| Peptide Fragments | 3 | 2021 | 242 | 0.370 |
Why?
| Obesity | 1 | 2018 | 1202 | 0.360 |
Why?
| Autophagy | 3 | 2024 | 202 | 0.350 |
Why?
| Lipid Peroxidation | 2 | 2007 | 132 | 0.340 |
Why?
| Polymerase Chain Reaction | 2 | 2000 | 531 | 0.340 |
Why?
| Signal Transduction | 4 | 2018 | 1753 | 0.330 |
Why?
| Codon, Nonsense | 3 | 2016 | 29 | 0.320 |
Why?
| Gene Expression Regulation | 3 | 2011 | 1062 | 0.320 |
Why?
| Humans | 22 | 2022 | 54284 | 0.320 |
Why?
| Protein Binding | 4 | 2018 | 736 | 0.310 |
Why?
| Genetic Markers | 3 | 2003 | 117 | 0.290 |
Why?
| Transcription, Genetic | 5 | 2015 | 418 | 0.280 |
Why?
| Disease Models, Animal | 6 | 2021 | 1639 | 0.280 |
Why?
| Molecular Dynamics Simulation | 2 | 2017 | 40 | 0.280 |
Why?
| Growth Inhibitors | 1 | 2005 | 32 | 0.270 |
Why?
| Receptor, Insulin | 1 | 2005 | 44 | 0.270 |
Why?
| Phosphorylation | 2 | 2017 | 614 | 0.260 |
Why?
| Lysosomes | 3 | 2024 | 91 | 0.260 |
Why?
| Cell Death | 2 | 2016 | 223 | 0.250 |
Why?
| Quantitative Trait, Heritable | 2 | 2001 | 30 | 0.240 |
Why?
| Kidney Tubules | 2 | 2017 | 99 | 0.240 |
Why?
| Hydrogen Peroxide | 2 | 2016 | 142 | 0.230 |
Why?
| Apolipoprotein E4 | 2 | 2024 | 19 | 0.220 |
Why?
| Amino Acid Sequence | 2 | 2021 | 767 | 0.220 |
Why?
| Benzylamines | 1 | 2021 | 18 | 0.200 |
Why?
| Cholinesterase Inhibitors | 1 | 2021 | 25 | 0.200 |
Why?
| Huntington Disease | 1 | 2021 | 27 | 0.200 |
Why?
| Microscopy, Fluorescence | 2 | 2012 | 198 | 0.200 |
Why?
| Alkaloids | 1 | 2021 | 37 | 0.200 |
Why?
| Protein Folding | 1 | 2021 | 52 | 0.200 |
Why?
| Taq Polymerase | 1 | 2000 | 6 | 0.190 |
Why?
| Base Pair Mismatch | 1 | 2000 | 24 | 0.190 |
Why?
| Oxyquinoline | 1 | 2020 | 7 | 0.190 |
Why?
| Indoles | 2 | 2020 | 289 | 0.190 |
Why?
| Chelating Agents | 1 | 2020 | 28 | 0.190 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2000 | 92 | 0.190 |
Why?
| RNA, Viral | 1 | 2021 | 141 | 0.190 |
Why?
| Recombination, Genetic | 1 | 2001 | 108 | 0.190 |
Why?
| Glioma | 1 | 2021 | 78 | 0.190 |
Why?
| Neuroprotective Agents | 1 | 2021 | 125 | 0.180 |
Why?
| RNA-Binding Proteins | 1 | 2021 | 136 | 0.180 |
Why?
| Drug Design | 1 | 2020 | 133 | 0.180 |
Why?
| Proteome | 1 | 2021 | 178 | 0.180 |
Why?
| Models, Animal | 3 | 2019 | 255 | 0.170 |
Why?
| Ubiquitin | 2 | 2018 | 51 | 0.170 |
Why?
| Hot Temperature | 2 | 2012 | 199 | 0.170 |
Why?
| Computer Simulation | 2 | 2017 | 332 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 124 | 0.160 |
Why?
| Cells, Cultured | 4 | 2016 | 1737 | 0.160 |
Why?
| Forkhead Transcription Factors | 3 | 2009 | 118 | 0.160 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 462 | 0.160 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 151 | 0.160 |
Why?
| Nucleotide Motifs | 1 | 2017 | 29 | 0.160 |
Why?
| Replication Origin | 1 | 2017 | 11 | 0.150 |
Why?
| Telomerase | 1 | 2017 | 30 | 0.150 |
Why?
| Cell Line | 2 | 2018 | 1153 | 0.150 |
Why?
| RNA, Transfer | 1 | 2017 | 25 | 0.150 |
Why?
| Genotype | 4 | 2017 | 599 | 0.150 |
Why?
| Mice | 6 | 2024 | 6413 | 0.150 |
Why?
| Acetylation | 1 | 2017 | 99 | 0.150 |
Why?
| Complement C1q | 1 | 2017 | 11 | 0.150 |
Why?
| Pericytes | 1 | 2017 | 15 | 0.150 |
Why?
| Complement C3 | 1 | 2017 | 31 | 0.150 |
Why?
| Complement Activation | 1 | 2017 | 43 | 0.150 |
Why?
| Intermediate Filament Proteins | 1 | 2016 | 12 | 0.150 |
Why?
| Detergents | 1 | 2016 | 17 | 0.150 |
Why?
| Carrier Proteins | 1 | 2018 | 359 | 0.140 |
Why?
| Mice, Transgenic | 1 | 2018 | 656 | 0.140 |
Why?
| Thermodynamics | 1 | 2016 | 43 | 0.140 |
Why?
| Transcriptome | 1 | 2019 | 346 | 0.140 |
Why?
| tau Proteins | 1 | 2016 | 30 | 0.140 |
Why?
| Solubility | 1 | 2016 | 75 | 0.140 |
Why?
| Catalytic Domain | 1 | 2016 | 62 | 0.140 |
Why?
| Young Adult | 2 | 2016 | 4318 | 0.140 |
Why?
| DNA Replication | 1 | 2017 | 152 | 0.140 |
Why?
| Pyridinium Compounds | 1 | 2015 | 17 | 0.140 |
Why?
| Promoter Regions, Genetic | 2 | 2011 | 520 | 0.140 |
Why?
| Cyclin-Dependent Kinases | 1 | 2015 | 35 | 0.140 |
Why?
| Ligands | 1 | 2016 | 230 | 0.140 |
Why?
| Blotting, Western | 2 | 2014 | 683 | 0.140 |
Why?
| Tissue Distribution | 1 | 2016 | 178 | 0.140 |
Why?
| Myofibroblasts | 1 | 2016 | 48 | 0.140 |
Why?
| DNA, Mitochondrial | 1 | 2017 | 186 | 0.140 |
Why?
| Homologous Recombination | 1 | 2015 | 43 | 0.140 |
Why?
| Benzimidazoles | 1 | 2015 | 54 | 0.130 |
Why?
| Peptide Nucleic Acids | 1 | 2015 | 17 | 0.130 |
Why?
| Rad51 Recombinase | 1 | 2015 | 21 | 0.130 |
Why?
| Reference Values | 1 | 2016 | 354 | 0.130 |
Why?
| Alleles | 2 | 2009 | 277 | 0.130 |
Why?
| Fertility | 1 | 2014 | 33 | 0.130 |
Why?
| Antineoplastic Agents | 2 | 2015 | 1300 | 0.130 |
Why?
| Fluorescent Antibody Technique | 1 | 2014 | 141 | 0.130 |
Why?
| Transcription Factors | 3 | 2009 | 622 | 0.130 |
Why?
| Protein Multimerization | 1 | 2014 | 54 | 0.120 |
Why?
| Stress, Physiological | 3 | 2011 | 194 | 0.120 |
Why?
| Melphalan | 1 | 2015 | 180 | 0.120 |
Why?
| Genes, Helminth | 2 | 2006 | 5 | 0.120 |
Why?
| Macrophages | 1 | 2017 | 405 | 0.120 |
Why?
| Renal Insufficiency, Chronic | 1 | 2017 | 182 | 0.120 |
Why?
| Models, Molecular | 3 | 2020 | 423 | 0.110 |
Why?
| Drug Resistance, Neoplasm | 1 | 2015 | 309 | 0.110 |
Why?
| Recombinant Fusion Proteins | 2 | 2021 | 206 | 0.110 |
Why?
| Case-Control Studies | 1 | 2016 | 1228 | 0.110 |
Why?
| Life Expectancy | 1 | 2012 | 40 | 0.110 |
Why?
| Lipoprotein Lipase | 1 | 2012 | 15 | 0.110 |
Why?
| Age Factors | 1 | 2016 | 1198 | 0.110 |
Why?
| Endothelial Cells | 2 | 2011 | 294 | 0.110 |
Why?
| Locomotion | 1 | 2012 | 83 | 0.100 |
Why?
| Microscopy, Confocal | 1 | 2012 | 110 | 0.100 |
Why?
| Scavenger Receptors, Class E | 2 | 2011 | 217 | 0.100 |
Why?
| Data Mining | 1 | 2011 | 38 | 0.100 |
Why?
| Fluorescent Dyes | 1 | 2012 | 116 | 0.100 |
Why?
| Down-Regulation | 2 | 2011 | 388 | 0.100 |
Why?
| Antimitotic Agents | 1 | 2010 | 4 | 0.100 |
Why?
| Triglycerides | 1 | 2012 | 195 | 0.100 |
Why?
| Oxidants | 1 | 2011 | 64 | 0.100 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2011 | 96 | 0.100 |
Why?
| Multiple Myeloma | 2 | 2015 | 3035 | 0.090 |
Why?
| Adult | 2 | 2016 | 14207 | 0.090 |
Why?
| Fatty Acids | 1 | 2011 | 174 | 0.090 |
Why?
| Histoplasma | 1 | 2009 | 29 | 0.090 |
Why?
| Cisplatin | 1 | 2012 | 352 | 0.090 |
Why?
| Lipoproteins, LDL | 1 | 2011 | 195 | 0.090 |
Why?
| Epistasis, Genetic | 2 | 2017 | 42 | 0.090 |
Why?
| Histoplasmosis | 1 | 2009 | 53 | 0.090 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2007 | 151 | 0.090 |
Why?
| Angiogenesis Inhibitors | 1 | 2010 | 203 | 0.090 |
Why?
| Time Factors | 4 | 2019 | 3213 | 0.080 |
Why?
| Aged, 80 and over | 1 | 2016 | 3431 | 0.080 |
Why?
| Evolution, Molecular | 1 | 2009 | 103 | 0.080 |
Why?
| Binding Sites | 1 | 2009 | 440 | 0.080 |
Why?
| Gene Expression | 2 | 2012 | 664 | 0.080 |
Why?
| Atherosclerosis | 1 | 2011 | 249 | 0.080 |
Why?
| Survival Rate | 1 | 2011 | 951 | 0.080 |
Why?
| Oogenesis | 1 | 2007 | 17 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 474 | 0.080 |
Why?
| Oxygen | 1 | 2010 | 361 | 0.080 |
Why?
| Acute Kidney Injury | 1 | 2012 | 403 | 0.080 |
Why?
| DNA Methylation | 1 | 2011 | 574 | 0.070 |
Why?
| Genes, Insect | 1 | 2006 | 7 | 0.070 |
Why?
| Kidney | 1 | 2012 | 820 | 0.070 |
Why?
| Cell Proliferation | 1 | 2011 | 1096 | 0.070 |
Why?
| Drosophila melanogaster | 1 | 2006 | 24 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 2 | 2021 | 1476 | 0.070 |
Why?
| Male | 5 | 2018 | 27334 | 0.070 |
Why?
| Environment | 1 | 2006 | 103 | 0.070 |
Why?
| Cell Line, Tumor | 3 | 2015 | 1550 | 0.070 |
Why?
| Models, Biological | 1 | 2009 | 823 | 0.070 |
Why?
| Isoenzymes | 1 | 2005 | 177 | 0.060 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2015 | 219 | 0.060 |
Why?
| Apoptosis | 1 | 2011 | 1300 | 0.060 |
Why?
| Up-Regulation | 2 | 2011 | 508 | 0.060 |
Why?
| Stress, Psychological | 1 | 2006 | 270 | 0.060 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 206 | 0.060 |
Why?
| Disease Progression | 2 | 2017 | 913 | 0.060 |
Why?
| Cytokines | 2 | 2017 | 676 | 0.060 |
Why?
| RNA, Messenger | 3 | 2017 | 1202 | 0.060 |
Why?
| Animals, Congenic | 1 | 2003 | 4 | 0.060 |
Why?
| Animals, Inbred Strains | 1 | 2003 | 5 | 0.060 |
Why?
| Aged | 1 | 2016 | 10054 | 0.050 |
Why?
| Cell Survival | 2 | 2015 | 657 | 0.050 |
Why?
| Electrophorus | 1 | 2021 | 5 | 0.050 |
Why?
| Butyrylcholinesterase | 1 | 2021 | 8 | 0.050 |
Why?
| Acetylcholinesterase | 1 | 2021 | 21 | 0.050 |
Why?
| Horses | 1 | 2021 | 51 | 0.050 |
Why?
| Crosses, Genetic | 1 | 2001 | 31 | 0.050 |
Why?
| Middle Aged | 1 | 2016 | 13088 | 0.050 |
Why?
| Lasers | 1 | 2021 | 141 | 0.050 |
Why?
| Phenotype | 2 | 2017 | 820 | 0.050 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 866 | 0.050 |
Why?
| Homozygote | 1 | 2001 | 60 | 0.050 |
Why?
| Biological Assay | 1 | 2021 | 55 | 0.050 |
Why?
| Heterozygote | 1 | 2001 | 96 | 0.050 |
Why?
| Templates, Genetic | 1 | 2000 | 17 | 0.050 |
Why?
| Chemistry Techniques, Synthetic | 1 | 2020 | 20 | 0.050 |
Why?
| Food Deprivation | 1 | 2000 | 29 | 0.050 |
Why?
| Molecular Structure | 1 | 2021 | 319 | 0.050 |
Why?
| DNA Transposable Elements | 1 | 2000 | 82 | 0.050 |
Why?
| Protein Structure, Secondary | 1 | 2020 | 99 | 0.050 |
Why?
| DNA Primers | 1 | 2000 | 225 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2001 | 193 | 0.050 |
Why?
| Peptides | 1 | 2021 | 276 | 0.050 |
Why?
| Structure-Activity Relationship | 1 | 2021 | 423 | 0.050 |
Why?
| HEK293 Cells | 1 | 2020 | 245 | 0.040 |
Why?
| Anisomycin | 1 | 2019 | 3 | 0.040 |
Why?
| Dipyrone | 1 | 2019 | 3 | 0.040 |
Why?
| Camptothecin | 1 | 2019 | 16 | 0.040 |
Why?
| Benzazepines | 1 | 2019 | 20 | 0.040 |
Why?
| Azacitidine | 1 | 2019 | 37 | 0.040 |
Why?
| Protein Unfolding | 1 | 2018 | 5 | 0.040 |
Why?
| Protein Conformation | 1 | 2018 | 226 | 0.040 |
Why?
| Sensitivity and Specificity | 1 | 2000 | 923 | 0.040 |
Why?
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 14 | 0.040 |
Why?
| Apolipoprotein E3 | 1 | 2017 | 8 | 0.040 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 74 | 0.040 |
Why?
| Cell Line, Transformed | 1 | 2017 | 88 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2019 | 514 | 0.040 |
Why?
| Molecular Docking Simulation | 1 | 2017 | 83 | 0.040 |
Why?
| Wnt3A Protein | 1 | 2017 | 13 | 0.040 |
Why?
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 21 | 0.040 |
Why?
| Extracellular Matrix Proteins | 1 | 2017 | 75 | 0.040 |
Why?
| Cell Communication | 1 | 2017 | 72 | 0.040 |
Why?
| Indolizines | 1 | 2015 | 11 | 0.040 |
Why?
| Wnt Signaling Pathway | 1 | 2017 | 94 | 0.030 |
Why?
| Ureteral Obstruction | 1 | 2017 | 70 | 0.030 |
Why?
| Cyclic N-Oxides | 1 | 2015 | 15 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2017 | 128 | 0.030 |
Why?
| Fibrosis | 1 | 2017 | 208 | 0.030 |
Why?
| Folic Acid | 1 | 2017 | 139 | 0.030 |
Why?
| S Phase | 1 | 2015 | 19 | 0.030 |
Why?
| Mice, SCID | 1 | 2015 | 196 | 0.030 |
Why?
| Drug Synergism | 1 | 2015 | 171 | 0.030 |
Why?
| Genes, BRCA1 | 1 | 2015 | 24 | 0.030 |
Why?
| Mice, Knockout | 1 | 2017 | 926 | 0.030 |
Why?
| DNA Damage | 1 | 2015 | 357 | 0.030 |
Why?
| Receptors, Lipoprotein | 1 | 2012 | 8 | 0.030 |
Why?
| Angiopoietins | 1 | 2012 | 7 | 0.030 |
Why?
| Azo Compounds | 1 | 2012 | 12 | 0.030 |
Why?
| Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 16 | 0.030 |
Why?
| Neutrophil Infiltration | 1 | 2012 | 29 | 0.030 |
Why?
| Melanins | 1 | 2012 | 30 | 0.030 |
Why?
| Intracellular Space | 1 | 2012 | 31 | 0.030 |
Why?
| Coloring Agents | 1 | 2012 | 84 | 0.030 |
Why?
| Adipose Tissue, White | 1 | 2012 | 39 | 0.030 |
Why?
| Necrosis | 1 | 2012 | 208 | 0.030 |
Why?
| Intercellular Junctions | 1 | 2010 | 8 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2017 | 1999 | 0.020 |
Why?
| Antibodies, Neutralizing | 1 | 2011 | 75 | 0.020 |
Why?
| Imaging, Three-Dimensional | 1 | 2012 | 171 | 0.020 |
Why?
| Cell Hypoxia | 1 | 2010 | 87 | 0.020 |
Why?
| Body Weight | 1 | 2012 | 578 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 635 | 0.020 |
Why?
| Microscopy | 1 | 2009 | 66 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1056 | 0.020 |
Why?
| Cell Differentiation | 1 | 2012 | 720 | 0.020 |
Why?
| Virulence | 1 | 2009 | 194 | 0.020 |
Why?
| Host-Pathogen Interactions | 1 | 2009 | 143 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2011 | 1138 | 0.020 |
Why?
| Liver | 1 | 2012 | 1225 | 0.020 |
Why?
| Female | 2 | 2017 | 28441 | 0.010 |
Why?
| Chromosomes, Artificial, Yeast | 1 | 2000 | 6 | 0.010 |
Why?
| Sequence Homology | 1 | 2000 | 21 | 0.010 |
Why?
| Larva | 1 | 2000 | 23 | 0.010 |
Why?
| Gene Library | 1 | 2000 | 50 | 0.010 |
Why?
| DNA, Complementary | 1 | 2000 | 145 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2000 | 198 | 0.010 |
Why?
| Heat-Shock Proteins | 1 | 2000 | 87 | 0.010 |
Why?
|
|
Ayyadevara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|